Bicycle Therapeutics (BCYC) grants 60,000 stock options to CSO

Rhea-AI Filing Summary

Bicycle Therapeutics plc reported that Chief Scientific Officer Michael Skynner received a grant of 60,000 employee stock options on July 15, 2026. These options allow purchase of Ordinary Shares at an exercise price of $4.2100 per share, expire on July 15, 2036, and vest with one-fourth on July 15, 2027 and the remainder in 36 equal monthly installments thereafter.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Skynner Michael

Role CHIEF SCIENTIFIC OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy) F1	60,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 60,000 shares (Direct)

Footnotes (1)

1. F1. This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on July 15, 2027 and the remaining shares in 36 equal monthly installments thereafter.

Key Figures

Options granted: 60,000 options Exercise price: $4.2100 per share Underlying shares: 60,000 Ordinary Shares +3 more

6 metrics

Options granted 60,000 options Employee stock option grant to Chief Scientific Officer on July 15, 2026

Exercise price $4.2100 per share Conversion or exercise price of the employee stock option grant

Underlying shares 60,000 Ordinary Shares Shares underlying the employee stock option (right to buy)

Expiration date July 15, 2036 Expiration of the reported employee stock option grant

Vesting cliff date July 15, 2027 One-fourth of the total option shares vest on this date

Post-transaction derivative holdings 60,000 options Total derivative securities held following the reported transaction

Key Terms

Employee Stock Option (right to buy), conversion or exercise price, vest, Ordinary Shares

4 terms

Employee Stock Option (right to buy) financial

"Security title reported as Employee Stock Option (right to buy)"

conversion or exercise price financial

"Conversion or exercise price of 4.2100 per share for the option"

vest financial

"This option shall vest with respect to one-fourth of the total number of shares"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Ordinary Shares financial

"Underlying security title identified as Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/17/2026 - 04:15 PM Accepted by SEC EDGAR 07/17/2026 - 04:15 PM Learn about SEC filing dates

FAQ

What insider transaction did BCYC executive Michael Skynner report?

Michael Skynner reported receiving a grant of 60,000 employee stock options on July 15, 2026. The options cover Ordinary Shares, carry a $4.2100 exercise price per share, and represent a compensation-related acquisition rather than an open-market stock purchase.

What are the key terms of Michael Skynner's new Bicycle Therapeutics (BCYC) stock options?

The grant consists of 60,000 employee stock options to buy Ordinary Shares at an exercise price of $4.2100 per share. The options expire on July 15, 2036, giving a 10-year term from the grant date.

How do Michael Skynner's BCYC stock options vest over time?

The options vest with respect to one-fourth of the shares on July 15, 2027. The remaining shares vest in 36 equal monthly installments thereafter, creating a multi-year vesting schedule tied to continued service.

How many Bicycle Therapeutics options does Michael Skynner hold after this Form 4 transaction?

Following this reported transaction, Michael Skynner holds 60,000 employee stock options related to this grant. This figure reflects his derivative securities position from this specific award as reported after the July 15, 2026 grant.

Was Michael Skynner's BCYC Form 4 transaction a market trade or an option grant?

The Form 4 shows a grant or award acquisition of options, coded as transaction type A, not a market purchase or sale. Skynner received 60,000 employee stock options from the company at a set exercise price of $4.2100 per share.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Skynner Michael

(Last) (First) (Middle)

C/O BICYCLE THERAPEUTICS PLC

BLOCKS A & B, PORTWAY BUILDING

(Street)

CAMBRIDGE CB21 6GS

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
BICYCLE THERAPEUTICS PLC [ BCYC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF SCIENTIFIC OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$4.21	07/15/2026		A		60,000		(1)	07/15/2036	Ordinary Shares	60,000	$0	60,000	D

Explanation of Responses:

1. This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on July 15, 2027 and the remaining shares in 36 equal monthly installments thereafter.

	/s/ Travis Thompson, Attorney-in-Fact	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)